Biotech start-up Vaccitech files for US IPO
Vaccitech owns the technology behind the COVID-19 vaccine developed by Oxford University and AstraZeneca
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Vaccitech
Vaccitech begins Phase 1 clinical study of VTP-300 immunotherapeutic to treat chronic Hepatitis B
Once the VTP-300 prime dose is confirmed, Vaccitech plans to initiate a Phase 1b/2a study, HBV002, in Q3 2020